Bayer (FRA:BAYN) received a €89.00 ($103.49) target price from equities research analysts at Sanford C. Bernstein in a report released on Monday. The brokerage presently has a “buy” rating on the healthcare company’s stock. Sanford C. Bernstein’s target price suggests a potential upside of 17.09% from the company’s current price.

A number of other research firms have also weighed in on BAYN. Jefferies Financial Group set a €123.00 ($143.02) price objective on Bayer and gave the stock a “buy” rating in a research note on Monday, June 4th. UBS Group set a €130.00 ($151.16) price objective on Bayer and gave the stock a “buy” rating in a research note on Friday, June 1st. Warburg Research set a €118.00 ($137.21) price objective on Bayer and gave the stock a “neutral” rating in a research note on Monday, June 4th. Kepler Capital Markets set a €104.00 ($120.93) price objective on Bayer and gave the stock a “neutral” rating in a research note on Monday, June 4th. Finally, equinet set a €118.00 ($137.21) price objective on Bayer and gave the stock a “buy” rating in a research note on Monday, June 4th. Seven investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of €99.20 ($115.35).

FRA BAYN opened at €76.01 ($88.38) on Monday. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: Closed-End Mutual Funds

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.